(a)
In general
A manufacturer that is the sole manufacturer of a drug—
(1)
that is—
(C)
intended for use in the prevention of a debilitating disease or condition;
(2)
for which an application has been approved under section
355
(b) or
355
(j) of this title; and
(3)
that is not a product that was originally derived from human tissue and was replaced by a recombinant product,
shall notify the Secretary of a discontinuance of the manufacture of the drug at least 6 months prior to the date of the discontinuance.
(b)
Reduction in notification period
The notification period required under subsection (a) of this section for a manufacturer may be reduced if the manufacturer certifies to the Secretary that good cause exists for the reduction, such as a situation in which—
(1)
a public health problem may result from continuation of the manufacturing for the 6-month period;
(2)
a biomaterials shortage prevents the continuation of the manufacturing for the 6-month period;
(3)
a liability problem may exist for the manufacturer if the manufacturing is continued for the 6-month period;
(4)
continuation of the manufacturing for the 6-month period may cause substantial economic hardship for the manufacturer;
(5)
the manufacturer has filed for bankruptcy under chapter 7 or 11 of title
11; or
(6)
the manufacturer can continue the distribution of the drug involved for 6 months.
(c)
Distribution
To the maximum extent practicable, the Secretary shall distribute information on the discontinuation of the drugs described in subsection (a) of this section to appropriate physician and patient organizations.